GENE ONLINE|News &
BeiGene’s Brukinsa Bags Second FDA Approval, to Rival Imbruvica in Treating a Rare Cancer
On September 1st, BeiGene announced that the FDA has greenlit its Brukinsa (zanubrutinib), a small molecule inhibitor of Bruton’s tyrosine kinase (BTK) for treating adult patients with a rare type of lymphoma called Waldenström’s macroglobulinemia (WM).
This is Brukinsa's second FDA approval, after bagging authorization from the agency for treating Mantle Cell Lymphoma in 2019. Besides the US, the drug has received marketing approval in five countries for this indication. Before the latest FDA approval, Brukinsa was approved for treating WM in China and Canada.
This is Brukinsa's second FDA approval, after bagging authorization from the agency for treating Mantle Cell Lymphoma in 2019. Besides the US, the drug has received marketing approval in five countries for this indication. Before the latest FDA approval, Brukinsa was approved for treating WM in China and Canada.
GO Prime with only $1.49 now
LATEST
Sex Dimorphism in Obesity and the Impact of Estrogen Hormone Therapy on Cardiometabolic Health
2022-01-17
Study Reveals a Form of Four-Stranded DNA that Links Protein Deficiency and Premature Aging
2022-01-17
EVENT
